Project description
In situ drug delivery to the brain for CNS diseases
Neurodegenerative disorders affect millions of individuals worldwide and also have a tremendous impact on their families. Treatments are limited due to the inability of therapeutics to cross the blood–brain barrier and reach the causative cell population in the brain. To address this problem, the EU-funded iProg project is developing a clinically validated platform that can deliver drugs locally within the brain with minimal systemic exposure. Using this device, researchers will prepare for a clinical trial to deliver a novel neurotrophic therapy against frontotemporal degeneration, a type of dementia caused by mutations in the progranulin gene. Results will have important implications for the treatment of neurodegenerative disorders.
Fields of science
- medical and health sciencesbasic medicinepharmacology and pharmacydrug discovery
- medical and health scienceshealth sciencespublic health
- medical and health sciencesbasic medicineneurologydementiaalzheimer
- natural sciencesbiological sciencesgeneticsmutation
- medical and health sciencesbasic medicineneurologyamyotrophic lateral sclerosis
Programme(s)
Funding Scheme
SME-1 - SME instrument phase 1Coordinator
141 57 Huddinge
Sweden
See on map